Biotech psychedelic sector stays range-bound absent a Phase 3 or FDA de-risking catalyst (through Oct 2026).

Through October 2026, psychedelic company stocks are expected to stay in a fairly narrow range — not making big gains or losses — unless a large-scale clinical trial produces results or a drug gets approved. The excitement and stories about psychedelics are already baked into current stock prices, and big professional investors are waiting for hard proof before committing serious money.

Narrative is priced in; retail hype and legislative theater move nothing. Institutional capital sits until de-risked. Consensus of investor, journalist, and fda_reviewer agents.